This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.
Kite's Yescarta (axicabtagene ciloleucel) has been recommended for adults with diffuse large B‑cell lymphoma (DLBCL) that returns within a year of, or is resistant to, first-line chemoimmunotherapy.
Gilead Science and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) to treat certain forms of lymphoma.
Kite, a Gilead company, has announced that the European Commission (EC) has granted approval for use of Yescarta (axicabtagene ciloleucel) as a second-line treatment in adult patients with diffuse large
Yescarta (axicabtagene ciloleucel) reached $175m in relapsed/refractory large B-cell lymphoma and relapsed/refractory indolent follicular lymphoma in both the US and Europe.
Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).
The top-line results come from the phase 3 ZUMA-7 trial, which is investigating Yescarta (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line LBCL.
More from news
Approximately 1 fully matching, plus 51 partially matching documents found.
Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
No results were found
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....